Claire L. Amos

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer.

Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer.

Journal: The Journal of clinical investigation

Published: March 31, 2026

Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.

Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.

Journal: The Journal of clinical investigation

Published: March 31, 2026

Transdermal Estradiol Patches in Locally Advanced Prostate Cancer.

Transdermal Estradiol Patches in Locally Advanced Prostate Cancer.

Journal: The New England journal of medicine

Published: March 25, 2026

Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer.

Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 06, 2026

Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer.

Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 06, 2026

On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.

On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.

Journal: The Lancet. Oncology

Published: November 05, 2025

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.

Journal: The Lancet. Oncology

Published: March 13, 2025

Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data.

Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 10, 2025

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.

Journal: Cell

Published: January 23, 2025

Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047).

Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047).

Journal: European urology

Published: March 26, 2024

External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol.

External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol.

Journal: The Lancet. Digital health

Published: January 10, 2024

A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design.

A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: July 03, 2023

Showing 1-12 of 32

Last Updated: 09/26/2026